CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
about
The novel chemokine receptor, G-protein-coupled receptor 75, is expressed by islets and is coupled to stimulation of insulin secretion and improved glucose homeostasisThe crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanismHeterologous expression and purification of Vibrio proteolyticus (Aeromonas proteolytica) aminopeptidase: A rapid protocolRegulation of Chemokine Activity - A Focus on the Role of Dipeptidyl Peptidase IV/CD26Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine familyTruncation of macrophage-derived chemokine by CD26/ dipeptidyl-peptidase IV beyond its predicted cleavage site affects chemotactic activity and CC chemokine receptor 4 interactionThe role of chemokines in cutaneous allergic inflammation.Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.Chemokines and their receptors in infectious disease.Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system?Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.Proteolytic processing of SDF-1alpha reveals a change in receptor specificity mediating HIV-associated neurodegenerationLoss of CD26 protease activity in recipient mice during hematopoietic stem cell transplantation results in improved transplant efficiency.Oral CCR5 inhibitors: will they make it through?The LD78beta isoform of MIP-1alpha is the most potent CCR5 agonist and HIV-1-inhibiting chemokine.Soluble complexes of regulated upon activation, normal T cells expressed and secreted (RANTES) and glycosaminoglycans suppress HIV-1 infection but do not induce Ca(2+) signaling.Rational design of novel HIV-1 entry inhibitors by RANTES engineeringHIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokinesCharacterization of structure, dynamics, and detergent interactions of the anti-HIV chemokine variant 5P12-RANTES.In vivo regulation of chemokine activity by post-translational modification.Secreted mucosal antimicrobials in the female reproductive tract that are important to consider for HIV prevention.CD26/dipeptidylpeptidase IV-chemokine interactions: double-edged regulation of inflammation and tumor biology.The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.CD26/DPPIV signal transduction function, but not proteolytic activity, is directly related to its expression level on human Th1 and Th2 cell lines as detected with living cell cytochemistry.Peptidase activity of dipeptidyl aminopeptidase IV produced by Porphyromonas gingivalis is important but not sufficient for virulence.CXCR7/ACKR3-targeting ligands interfere with X7 HIV-1 and HIV-2 entry and replication in human host cells.Recent developments in modulating chemokine networks
P2860
Q24319758-746E4411-B00C-4154-A2D1-12C59230A62DQ27640960-768B4A33-B501-4C0C-B907-DF4655B8E6F6Q27653876-C8C4E27F-5CA5-423F-86D0-61EA3B4DEA6BQ28072580-039668E3-41EB-4C6B-8C82-7D5E86C39262Q28199376-FB5ABCCB-9BEF-46D4-AA3C-2344019AEA24Q28296438-F6CFF768-BDBC-42ED-834A-9C2A5229E36DQ33737280-DBA75D2B-CECB-421F-AAF8-EE6C943D6B0FQ33846502-68E579F9-5F7C-4193-95BF-7EC0D1D05D2BQ34129756-359CE06D-8FE4-4A11-AE14-E3608A3B9C05Q34510719-B114D313-E471-42DB-9A4E-71E32F012F84Q35113121-FCFDA044-5BCF-487B-944D-5BCA7409B730Q35189265-71AD2118-CF77-4A92-819E-0F2445F20F89Q35539844-AD02551A-BEE3-458E-A82B-4E1EF7C604BCQ36403665-A3A26766-71F1-4F1C-AFFB-F1666C7D77C9Q36458354-B656CA64-B344-40A5-BC98-6336CA2118FCQ36736256-678CCBDB-23C4-4E87-A382-7DD2E92B6525Q36746649-546F5CE1-E4CC-4E71-8F04-A620348E1B33Q36793736-A537EDD0-6999-425E-8A3F-BAA3AB66E55DQ36915528-E5F3E8EB-A7FC-4AF6-AF40-EF025A324020Q37368217-A263EC48-06D6-4047-87C5-0EF0C396AEE5Q38102877-80624DAC-6E86-4E2B-9440-7E08241883F4Q38206217-526CB7F8-1ADB-4D5E-9CC1-3557EAE1E5C6Q38690194-25EC0A2D-9251-405F-B9F5-C29C503BF523Q38877913-E61B151F-7DCE-40AF-B132-BE6E60478371Q40710017-494F6E3B-EF47-493E-ACCC-AB578DE2072BQ52552452-6DC2B82D-E41D-464A-9CBD-5AF4B41BA57EQ54976504-882351A2-6BDA-4A7E-A6DC-F33E10998D4FQ57019193-E492587D-E1F9-40D1-869D-6AF876A9F6BD
P2860
CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
@en
CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
@nl
type
label
CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
@en
CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
@nl
prefLabel
CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
@en
CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity.
@nl
P2093
P50
P1433
P1476
CD26-processed RANTES(3-68), but not intact RANTES, has potent anti-HIV-1 activity
@en
P2093
P304
P356
10.1016/S0166-3542(98)00039-4
P577
1998-10-01T00:00:00Z